These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34094676)

  • 61. Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis.
    D'Angelo D; De Martino M; Arra C; Fusco A
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31487906
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.
    Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
    Cancer Cell; 2023 Jun; 41(6):1198. PubMed ID: 37311416
    [No Abstract]   [Full Text] [Related]  

  • 63. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
    Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
    Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Publisher Correction: HMGA1-pseudogene7 transgenic mice develop B cell lymphomas.
    De Martino M; De Biase D; Forzati F; Credendino SC; Palma G; Barbieri A; Arra C; Paciello O; Gaudio E; Ponzoni M; De Vita G; Chieffi P; Bertoni F; Fusco A; Esposito F
    Sci Rep; 2021 Jun; 11(1):12741. PubMed ID: 34117291
    [No Abstract]   [Full Text] [Related]  

  • 65. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting.
    Ayuk FA; Berger C; Badbaran A; Zabelina T; Sonntag T; Riecken K; Geffken M; Wichmann D; Frenzel C; Thayssen G; Zeschke S; Kröger N; Fehse B
    Blood Adv; 2021 Jun; 5(11):2523-2527. PubMed ID: 34100900
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
    Castillo JJ; Beltran BE; Malpica L; Marques-Piubelli ML; Miranda RN
    Leuk Lymphoma; 2021 Dec; 62(12):2845-2853. PubMed ID: 34151703
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
    Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
    Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.
    Bram Ednersson S; Stern M; Fagman H; Nilsson-Ehle H; Hasselblom S; Thorsell A; Andersson PO
    Leuk Lymphoma; 2021 Oct; 62(10):2360-2373. PubMed ID: 34114929
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing CAR T cell therapy in lymphoma.
    Qualls D; Salles G
    Hematol Oncol; 2021 Jun; 39 Suppl 1():104-112. PubMed ID: 34105817
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of tazemetostat in relapsed/refractory follicular lymphoma.
    von Keudell G; Salles G
    Ther Adv Hematol; 2021; 12():20406207211015882. PubMed ID: 34104370
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment for Relapsed/Refractory Acute Myeloid Leukemia.
    Thol F; Heuser M
    Hemasphere; 2021 Jun; 5(6):e572. PubMed ID: 34095756
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors.
    Hu X; Xiao Y; Sun J; Ji B; Luo S; Wu B; Zheng C; Wang P; Xu F; Cheng K; Hua H; Li D
    Acta Pharm Sin B; 2021 May; 11(5):1148-1157. PubMed ID: 34094825
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CAR-T cells: Early successes in blood cancer and challenges in solid tumors.
    Dana H; Chalbatani GM; Jalali SA; Mirzaei HR; Grupp SA; Suarez ER; Rapôso C; Webster TJ
    Acta Pharm Sin B; 2021 May; 11(5):1129-1147. PubMed ID: 34094824
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HMGA1 is a Prognostic Biomarker and Correlated with Glycolysis in Lung Adenocarcinoma.
    Ma Y; Ma X; Du B; Li X; Li Y
    J Cancer; 2024; 15(10):2913-2927. PubMed ID: 38706894
    [No Abstract]   [Full Text] [Related]  

  • 75. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma.
    De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
    Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.
    Wang L; Zhang J; Xia M; Liu C; Zu X; Zhong J
    Int J Biol Sci; 2022; 18(11):4414-4431. PubMed ID: 35864955
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of HMGA1 protein in gastroenteropancreatic neuroendocrine tumors.
    De Martino M; Pellecchia S; Esposito F; Tosti N; Quintavalle C; Eppenberger-Castori S; Carafa V; Righi A; Chieffi P; Fusco A; Terracciano LM; Pallante P
    Cell Cycle; 2022 Jun; 21(12):1335-1346. PubMed ID: 35282770
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Critical role of the high mobility group A proteins in hematological malignancies.
    De Martino M; Esposito F; Fusco A
    Hematol Oncol; 2022 Feb; 40(1):2-10. PubMed ID: 34637548
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.